Servicios Personalizados
Articulo
Indicadores
Links relacionados
- Citado por Google
- Similares en Google
Compartir
African Journal of Laboratory Medicine
versión On-line ISSN 2225-2010
versión impresa ISSN 2225-2002
Resumen
WILLIAMS, Victor et al. GeneXpert rollout in three high-burden tuberculosis countries in Africa: A review of pulmonary tuberculosis diagnosis and outcomes from 2001 to 2019. Afr. J. Lab. Med. [online]. 2022, vol.11, n.1, pp.1-8. ISSN 2225-2010. http://dx.doi.org/10.4102/ajlm.v11i1.1811.
BACKGROUND: The rollout of GeneXpert aimed at increasing early diagnosis of tuberculosis to improve treatment outcomes and global tuberculosis targets. OBJECTIVE: This study evaluated trends in tuberculosis diagnosis and outcomes pre- and post-introduction of GeneXpert in three African countries - the Democratic Republic of the Congo (DRC), Nigeria and South Africa. METHODS: Data from 2001 to 2019 were extracted from the World Health Organization's data repository. Descriptive analysis, paired t-tests and interrupted time series models were used. RESULTS: Estimated tuberculosis incidence decreased from 327/100 000 to 324/100 000 in the DRC, and from 1220/100 000 to 988/100 000 in South Africa. Incidence remained at 219/100 000 in Nigeria. The tuberculosis case notification rate did not change significantly. Increases in the new case treatment success rates were statistically significant (DRC: p = 0.0201; Nigeria: p = 0.0001; South Africa: p = 0.0017); decreases in mortality were also statistically significant (DRC: p = 0.0264; Nigeria: p = 0.0001; South Africa: p < 0.0001). Time series models showed insignificant increases in new tuberculosis cases in DRC (n = 1856, p = 0.085) and Nigeria (n = 785, p = 0.555) from 2011 to 2019; and a statistically significant decrease in South Africa (n = 15 269, p = 0.006). CONCLUSION: Improvements in tuberculosis treatment outcomes were achieved, but little progress has been made in new case notification due to varied implementation and scale-up of GeneXpert across the three countries. Implementation barriers need to be addressed to achieve the required tuberculosis targets.
Palabras clave : tuberculosis; GeneXpert; Xpert MTB/RIF; Africa; interrupted time series.